|
Catalog Number ECH060040J |
Device Problems
Peeled/Delaminated (1454); Obstruction of Flow (2423)
|
Patient Problem
Obstruction/Occlusion (2422)
|
Event Date 10/01/2022 |
Event Type
Injury
|
Event Description
|
The following information was obtained from a conference presentation: on an unknown date, in (b)(6) 2016, the patient underwent dialysis shunt construction in the right forearm using gore® acuseal vascular graft for renal failure.Postoperatively, the patient was treated with antiplatelet therapy and anticoagulation therapy, and vascular access intervention therapy(vaivt) was performed every few months to keep the graft patent.On an unknown date in (b)(6) 2022, graft occlusion occurred once every 1-2 weeks, and graft delamination was suspected, but vaivt was performed first.Since frequent vaivt was required thereafter, a reintervention was performed.On (b)(6) 2022, preoperative ultrasonography confirmed the graft delamination, and the delamination site was replaced with new graft.The patient tolerated the procedure.
|
|
Manufacturer Narrative
|
Cbas® heparin surface incorporates carmeda heparin manufactured from heparin sodium api, which is covalently bound to the device surface and is essentially non-eluting.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|
|
Search Alerts/Recalls
|
|
|